tbuckley/cabot-search huggingface dataset:
Randomized trial of a home-based exercise intervention for patients with advanced colorectal cancer: Effects on physical functioning and activity levels.
Authors: Karen Basen-Engquist, Patricia A. Parker, Cathy Eng, Yisheng Li, David B. Johnson, Bryan K. Kee, Sajeve Samuel Thomas, Lucas Wong, Todd S. Crocenzi, Jaejoon Song, Michael Fisch
Journal: Journal of Clinical Oncology (2015)

9633 Background: Considerable evidence demonstrates the benefits of exercise for cancer survivors, but few studies focus on those living with advanced disease. We conducted a randomized trial of a home-based exercise intervention for patients with advanced colorectal cancer (CRC), and investigated the effects on physical functioning (primary) and physical activity. Methods: 152 patients with advanced CRC were recruited through the Community Clinical Oncology Program, and were randomized to: 1) a 4 month home-based exercise intervention (EX), or 2) a relaxation control group (R). Both groups received telephone coaching/prompts, instructional materials, and brief coaching and letters from their provider. The EX arm received pedometers and resistance bands. Participants completed self-reports of physical functioning and activity, and performance tasks (2-min step test, 8-ft up and go, arm curl test, 30-sec sit–to-stand test) at baseline and end of study (EOS). Linear mixed model analysis tested intervention arm effects on EOS outcomes, adjusting for baseline and accounting for random effects of study site and physician. Results: Of the 152 randomized patients, 55 (72%) in EX and 57 (75%) in R completed the study. No serious adverse events were attributable to the interventions. At EOS, the EX arm reported more light and moderate activity at EOS than the R arm (p = 0.003 and 0.002, respectively), and performed better on the 30-sec sit-to-stand than R group participants (p = 0.05), with a trend toward better performance on the 8-ft up-and-go (p = .12). There were no significant group differences in SF-36 physical functioning, step test, or arm curl test. Conclusions: In one of the first trials to test home-based exercise for patients with advanced CRC, EX effectively increased activity levels and improved select aspects of physical functioning, suggesting it may be a safe and useful intervention in this population. Clinical trial information: NCT00985400.Estimated effects of EX on physical functioning. Outcome Effect estimate (SE) p 30-sec sit-to-stand 1.1 (0.6) 0.05 8-ft Up-and-Go -0.9 (0.6) 0.12 2-min step 4.5 (4.7) 0.33 Arm curl 0.5 (0.7) 0.53 SF-36 Physical Functioning 3.2 (4.6) 0.49
A new French paradox: morbidly obese patients with NASH have less bulimia than those without NASH
Authors: C.M. Canivet, F. Cherikh, S. Patouraux, M. Hamm, M.-C. Saint-Paul, A. Tran, P. Gual, A. Iannelli, R. Anty
Journal: Journal of Hepatology (2017)
Evidence-based two-and-seven criteria according to tumor number and size best help to predict survival of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization
Authors: D. Xia, W. Bai, M. Huang, J. Sun, E. Wang, H. Li, J. Li, H. Zhao, X. Pan, S. Chen, W. Gong, X. Zhu, G. Shao, W. Mu, Z. Chen, J. Wu, J. Liu, J. Li, J. Song, C. Zhang, H. Shi, Z. Li, S. Yang, W. Wang, Y. Zheng, J. Xu, W. Wang, J. Yuan, X. Li, J. Niu, Z. Yin, D. Fan, J. Xia, G. Han
Journal: Journal of Hepatology (2017)
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial diffuse large B-cell lymphoma.
Authors: Niels Murawski, Samira Zeynalova, Gerhard Held, Marita Ziepert, Barbara Kempf, Andreas Viardot, Mathias Haenel, Mathias Witzens-Harig, Christian Ruebe, Jochen Fleckenstein, Carsten Zwick, Bertram Glass, Norbert Schmitz, Michael Pfreundschuh
Journal: Journal of Clinical Oncology (2013)

8566 Background: The role of radiotherapy and intrathecal prophylaxis in extralymphatic craniofacial involvement of aggressive B-cell lymphoma remains to be determined in the rituximab era. Methods: In a retrospective subgroup analysis of 9 consecutive prospective DSHNHL trials covering all DLBCL risk groups from 18 to 60 years of age, patients with and without craniofacial involvement were compared with respect to clinical presentation, event-free and overall survival. Results: 336 sites of extralymphatic craniofacial involvement were observed in 284/3840 (7.4%) patients (orbita: 30, paranasal sinuses: 90; main nasal cavity: 38, tongue: 26, remaining oral cavity: 99, salivary glands: 53). In a multivariable analysis adjusting for IPI risk factors the addition of rituximab improved EFS and OS in both patients with and without craniofacial involvement. The 141 responding patients who received radiotherapy to sites of craniofacial involvement had a similar 3-year event-free (79% vs 79%; p=0.835) and 3-year overall survival (88% vs. 85%; p=0.311) when compared with the 56 patients who did not receive radiotherapy. Without rituximab, the 2-year-rate of cumulative risk of CNS disease was increased in 205 patients with compared to 2586 patients without craniofacial involvement (4.2% vs. 2.8%; p=0.038), while this difference disappeared in patients who received CHOP(like) chemotherapy in combination with rituximab (1.7% in 77 patients with compared to 2.9% in 946 patients without craniofacial involvement; p=0.868). Of 85 patients with craniofacial involvement who received intrathecal prophylaxis with methotrexate, the 2-year-rate of cumulative risk of CNS disease was 4.3% compared to 2.3% in 189 patients who did not (p=0.995). Conclusions: Rituximab eliminates the increased risk for CNS disease in patients with craniofacial involvement. As a practical consequence intrathecal prophylaxis and radiotherapy to sites of craniofacial involvement should not be given any more.
Biologic Pathways of Cancer-Cachexia Syndrome (Muscle and Fat Wasting) Impact Clinical Outcomes in Aggressive B-Cell Non-Hodgkin Lymphoma
Authors: Reem Karmali, Vineela Chukkapalli, Palmi Shah, Taha Alrifai, Palmi Shah, Ibtihaj A Fughhi, Ronald Ng, Sanjib Basu, Kelly Szymanski, Parameswaran Venugopal, Jeffrey A. Borgia
Journal: Blood (2016)
Abstract 390: VLDL Exits From The Endoplasmic Reticulum In A Specialized VLDL-transporting-vesicle (VTV) In Rat Primary Hepatocytes.
Authors: Shadab A Siddiqi
Journal: Circulation (2007)

Transport of very low-density lipoprotein (VLDL) from its site of synthesis, the endoplasmic reticulum (ER), to the Golgi is required for its eventual secretion from hepatocytes. This step represents a potential therapeutic target in controlling VLDL export and thus control of its metabolic derivative, LDL, the major carrier of cholesterol and determinant of atherosclerosis. The present study was designed to understand how VLDL exits from the ER at the molecular level. We developed an in vitro ER-budding assay in which rat liver ER (500 ug) was pre-loaded with 14 C-triacylglycerol (TAG) to mark VLDL and 3 H-proteins to mark newly synthesized proteins. The ER was incubated with rat liver cytosol (1 mg), GTP, and ATP at 37 o C for 30 min. The reaction mix was fractionated on a continuous sucrose gradient and the distribution of 14 C-TAG and 3 H-protein across the gradient was determined. 14 C-TAG was found in the light density region of the gradient, the expected place for TAG-rich VLDL carrying vesicles whereas 3 H-proteins appeared in the mid portion, the expected place in the gradient for protein vesicles. We examined the distribution of apolipoprotein B100 (apoB100), a marker for VLDL and albumin (a typical liver secretory protein) across the same gradient by Western blotting. As expected, apoB100 was distributed in light fractions whereas albumin was mainly in the mid portion of the gradient. These data show that VLDL and albumin are transported in vesicles of differing density. We hypothesize that a specialized vesicle is utilized for VLDL transport, which we name the VLDL-transporting-vesicle (VTV). Our results show that the release of VTV from rat liver ER requires cytosol, GTP, Sar1 (a GTPase), ATP, and incubation at 37 o C. VTV was sealed as judged by apoB100 signal post proteinase K treatment. VTVs concentrate ApoB100, Sar1, and exclude ER-resident protein calnexin. VTV fuses with liver cis -Golgi and delivers its cargo, VLDL, to the Golgi lumen. 2D-gels and electron microscopy data reveal that VTVs are different in their protein composition and are larger in size when compared to albumin carrying vesicles. In conclusion, we have identified and characterized a new ER-derived vesicle, VTV, which transports nascent VLDL from the ER to the Golgi in primary hepatocytes.
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Authors: Catherine C. Smith, Amy Paguirigan, Grace R. Jeschke, Kimberly C. Lin, Evan Massi, Theodore Tarver, Chen-Shan Chin, Saurabh Asthana, Adam Olshen, Kevin J. Travers, Susana Wang, Mark J. Levis, Alexander E. Perl, Jerald P. Radich, Neil P. Shah
Journal: Blood (2017)
SAF score effectively identifies NAFLD subjects at high risk of subsequent liverrelated but not cardiovascular or malignancy-associated mortality and morbidity
Authors: M. Strasser, A. Feldman, M. Schranz, L. Stechemesser, L. Denkmayr, S. Ruhaltinger, G. Strebinger, U. Huber-Schönauer, D. Niederseer, S. Zandanell, B. Paulweber, E. Aigner, C. Datz
Journal: Journal of Hepatology (2017)
CHOP chemotherapy plus rituximab compared with CHOP alone in patients with diffuse large B-cell lymphoma, from Indian subcontinent.
Authors: Vijay Gandhi Linga, Raghunadharao Digumarti, Rahul Narayan Maddi, Vamshi Krishna Reddy Goteke, Sadashivudu Gundeti, Narender Kumar Thota, Pragnya Coca
Journal: Journal of Clinical Oncology (2012)

e18545 Background: Outside the setting of the clinical trials there is very little data of CHOP chemotherapy plus Rituximab (CHOP-R) compared with standard CHOP in Indian population. We analyzed our cohort of patients diagnosed with Diffuse Large B cell Lymphoma (DLBCL). Primary objective was to compare CHOP with CHOP-R in term of PFS and OS. Methods: All the patients aged more than 21 years diagnosed with DLBCL (CD 20+) were retrospectively analyzed from Jan 2000 to June 2011. According to institute guideline staging and International Prognostic Index (IPI) risk grouping were done. Patients were started on standard cyclophoshomide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.5mg/m2 on day 1 and prednisolone 60mg/m2 day 1-5 (CHOP). Rituximab 375 mg/m2 was given on day 1 depending on the affordability/Insurance. Clinical evaluation was done after each cycle and response assessment with CT scan was done after third and sixth cycle. Progression free survival (PFS) was defined as progression during therapy, relapse, death and lost to follow up. Overall survival was defined as time till death and lost to follow up. Statistical analysis was done using Graph pad software and p value less than 0.05 was taken significant. Results: There were 67 patients in CHOP-R and 206 patients in CHOP arm. Basic characteristics and survival data are described in table 1, which are not distributed equally in two arms. The PFS in R-CHOP and CHOP arms were 40 and 9 months respectively (p=0.0008). The OS in R-CHOP and CHOP arms were 47 and 13 months respectively (p=0.007). Conclusions: There was statistical difference between the PFS and OS between the two arms. [Table: see text]
Phase II study: Induction chemotherapy &amp; transoral surgery as definitive tx for locally advanced oropharyngeal squamous cell carcinoma (OPSCC)—A novel approach.
Authors: Robert S. Siegel, Hind Rafei, Arjun Joshi, Khaled El-Shami, Reza Taheri, Hiwot Guebre-Xabiher, Nader Sadeghi
Journal: Journal of Clinical Oncology (2017)

6078 Background: The standard of care for OPSCC includes chemoradiation (CRT) or surgery with adjuvant radiation (RT). However, RT is associated with significant life long morbidity. We assessed the efficacy of a two-drug induction regimen, followed by transoral robotic assisted surgery (TORS) &amp; neck dissection for locally advanced OPSCC. Methods: This is an IRB approved single-arm phase II study for untreated stage III or IVA OPSCC patients (pts) with an ECOG &lt; 2 and GFR &gt; 50 cc. Induction chemotherapy consisted of cisplatin 75 mg/m2 and taxotere 75 mg/m2 every 21 days for 3 cycles. Tumor shrinkage was examined after each cycle. If the primary tumor was &gt; 80% smaller, pts underwent TORS and neck dissection(s). At post-op visits, flexible laryngoscopy, blood work, and imaging with PET/CT and/or MRI were done. Short and long term toxicity, progression-free survival (PFS) and overall survival (OS), and quality of life (QOL) were evaluated. Results: Nineteenpts were treated and 14 are available for analysis. Thirteen were male, 12 were Caucasian, 2 were African-American, and 13 were HPV+. Median age at diagnosis was 57. Tumors involved the tonsil (11 pts) and base of tongue (3 pts). Three pts were stage III, and 11 were stage IVA. Tumor size was reduced on average by 58%, 84% and 92% after the 1st, 2 nd and 3 rd induction cycles respectively. Pathologic complete remission of primary disease occurred in 11 pts and in 7 pts with cervical lymph node disease. Four pts were given dose-reduced chemo and one pt was changed to carboplatin per protocol because of renal dysfunction. In addition, adverse events included three patients with grade I fatigue, neuropathy or nausea. Pre vs post tx QOL scores were not significantly different. At a mean follow-up (f/u) of 13 months (range 2.5 to 19.7), 13 pts are alive and well. Three pts recurred, and were treated with salvage CRT. One pt died of metastatic disease. Conclusions: Cisplatin + Taxotere is an effective induction tx for OPSCC, Induction tx followed by transoral &amp; neck resections without RT is a promising tx model for OPSCC. It appears effective while avoiding adverse effects of RT. Longer f/u is required to assess its true efficacy. Clinical trial information: NCT02760667.
Smoking history as a risk factor for atrial fibrillation following robotic-assisted video-thoracoscopic pulmonary lobectomy
Authors: J. Glover, S. Reynolds, M. Echavarria, E. Ng, F. Velez-Cubian, C. Moodie, J. Garrett, J. Fontaine, E. Toloza
Journal: Annals of Oncology (2017)
Incidence and prevalence of recorded non-alcoholic fatty liver disease in four large European primary care databases covering 21.9 million adults
Authors: M. Alexander, K. Loomis, J. Fairburn-Beech, J. van der Lei, T. Duarte-Salles, D. Ansell, A. Pasqua, P. Rijnbeek, P. Avillach, S. Kendrick, D. Waterworth, N. Sattar, W. Alazawi
Journal: Journal of Hepatology (2017)
Is it safe for patients with minimal hepatic encephalopathy to drive?: A prospective study of 163 patients linking simulation with real-life crashes
Authors: M. M. Lauridsen, V. Ahluwalia, A. Unser, M. White, R. K. Sterling, R. T. Stravitz, S. C. Matherly, P. Puri, A. J. Sanyal, V. A. Luketic, M. S. Siddiqui, D. M. Heuman, M. Fuchs, J. S. Bajaj
Journal: Hepatology (2015)
Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis
Authors: Pierre-Antoine Juge, Raphaël Borie, Caroline Kannengiesser, Steven Gazal, Patrick Revy, Lidwine Wemeau-Stervinou, Marie-Pierre Debray, Sébastien Ottaviani, Sylvain Marchand-Adam, Nadia Nathan, Gabriel Thabut, Christophe Richez, Hilario Nunes, Isabelle Callebaut, Aurélien Justet, Nicolas Leulliot, Amélie Bonnefond, David Salgado, Pascal Richette, Jean-Pierre Desvignes, Huguette Lioté, Philippe Froguel, Yannick Allanore, Olivier Sand, Claire Dromer, René-Marc Flipo, Annick Clément, Christophe Béroud, Jean Sibilia, Baptiste Coustet, Vincent Cottin, Marie-Christophe Boissier, Benoit Wallaert, Thierry Schaeverbeke, Florence Dastot le Moal, Aline Frazier, Christelle Ménard, Martin Soubrier, Nathalie Saidenberg, Dominique Valeyre, Serge Amselem, Catherine Boileau, Bruno Crestani, Philippe Dieudé
Journal: European Respiratory Journal (2017)

Despite its high prevalence and mortality, little is known about the pathogenesis of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Given that familial pulmonary fibrosis (FPF) and RA-ILD frequently share the usual pattern of interstitial pneumonia and common environmental risk factors, we hypothesised that the two diseases might share additional risk factors, including FPF-linked genes. Our aim was to identify coding mutations of FPF-risk genes associated with RA-ILD.We used whole exome sequencing (WES), followed by restricted analysis of a discrete number of FPF-linked genes and performed a burden test to assess the excess number of mutations in RA-ILD patients compared to controls.Among the 101 RA-ILD patients included, 12 (11.9%) had 13 WES-identified heterozygous mutations in the TERT, RTEL1, PARN or SFTPC coding regions. The burden test, based on 81 RA-ILD patients and 1010 controls of European ancestry, revealed an excess of TERT, RTEL1, PARN or SFTPC mutations in RA-ILD patients (OR 3.17, 95% CI 1.53-6.12; p=9.45×10-4). Telomeres were shorter in RA-ILD patients with a TERT, RTEL1 or PARN mutation than in controls (p=2.87×10-2).Our results support the contribution of FPF-linked genes to RA-ILD susceptibility.
The combination of Fibroscan with blood markers in the fibrometerVCTE significantly reduces the use of liver biopsy for the assessment of advanced fibrosis in non-alcoholic fatty liver disease
Authors: J. Boursier, J. Vergniol, A. Lannes, J.-B. Hiriart, F. Oberti, B. Le Bail, S. Michalak, F. Chermak, S. Bertrais, J. Foucher, I. Fouchard-Hubert, M. Charbonnier, M.-C. Rousselet, P. Cales, V. de Ledinghen
Journal: Journal of Hepatology (2017)
Single-nucleotide polymorphisms (SNPs) associated with outcome: The first experience in thymic tumors.
Authors: Rossana Berardi, Silvia Pagliaretta, Alessandro Brunelli, Vittorio Paolucci, Gaia Goteri, Majed Refai, Cecilia Pompili, Agnese Savini, Giulia Marcantognini, Francesca Morgese, Silvia Rinaldi, Mariagrazia De Lisa, Miriam Caramanti, Mariangela Torniai, Michela Tiberi, Consuelo Ferrini, Paola Mazzanti, Azzurra Onofri, Antonio Zizzi, Stefano Cascinu
Journal: Journal of Clinical Oncology (2014)

e18557 Background: Thymomas (T) display heterogeneity from morphologic point of view, clinical behaviour, immunohistochemical markers and molecular profiling. Thus improving our understanding of the molecular biology of thymic malignancies (TM) represents a key challenge in the treatment of these tumors. Methods: The genomic DNA of 93 consecutive patients (pts) undergoing total thymectomy was extracted from paraffin-embedded tissue. We studied the following SNPs: HIF-1a (rs2057482T>C, rs1951795A>C, rs2301113C>A, rs10873142C>T, rs11158358G>C, rs12434438G>A, rs11549465C>T, rs11549467G>A), VEGF-A(rs2010963G>C, rs699947A>C), VEGFR-2 (rs2305948C>T, rs1870377T>A), VEGFR-3 (rs307826T>C,rs307821C>A), PDGFR-A (rs35597368C>T) and ERCC1 (rs11615A>G). Gene polymorphisms were determined by Real-Time PCR using TaqMan assays. Results: 93 pts were included, M/F ratio =35/58. All the pts underwent surgery: 43 for T, 14 for thymic carcinomas (TC) and 36 for TH. The frequency PDGFRa rs35597368T SNPs (95.24%) was significantly higher in TM if compared population (86%,p=0.012), thus suggesting that it may represent a risk factor. On the other hand, the frequency of HIF-1a SNPs (rs2057482C, rs11549465C,rs1951795C, rs2301113A, rs10873142T, rs11158358C, rs12434438A) resulted lower than in the general population (p<0.05). In particular, frequencies of HIF1a rs1951795C, rs2301113A, rs12434438A were significantly lower in TM than in TH and in population, suggesting a protective role. Furthermore, VEGFR3 rs307821C SNPs was higher in T than in TC (79.5% vs 72%,p=0.0371), and therefore it seems to be related to a lower grade of malignancy. Finally, the following were significantly correlated with a better overall survival: VEGFR-3 rs307826C, VEGFR-2 rs1870377A, PDGFR-A rs35597368T/C, HIF1a rs2301113C, rs2057482C/T, rs1951795C, rs11158358G/C and rs10873142T/C, ERCC1 rs11615A (p<0.05). Conclusions: To the best of our knowledge this is the first study analyzing the angiogenetic variants in TH and TM representing a further asset in the definition of high-risk pts after curative resection, also driving the selection of more aggressive adjuvant treatment in this subgroup of pts.
Serious Games: The Future of Psychotherapy? Proposal of an Integrative Model
Authors: Thomas Fovet, Jean-Arthur Micoulaud-Franchi, Renaud Jardri, David E.J. Linden, Ali Amad
Journal: Psychotherapy and Psychosomatics (2017)

avid E d m u n d Joh a n n e s a n d Am a d, Ali 2 0 1 7 .
Self-assessment system of febrile neutropenia (FN) by patients receiving ambulatory chemotherapy for solid tumor.
Authors: Akihito Kitao, Koji Matsumoto, Maki Tanioka, Shunichi Negoro
Journal: Journal of Clinical Oncology (2012)

e19548 Background: Febrile neutropenia is one of the oncology emergencies, which usually should be timely assessed and treated at the hospital. In some areas of Japan, however, medical resources are limited in especially nights and holidays. In Hyogo Cancer Center department of medical oncology, majority of pts have breast and gynecologic (GYN) malignant disease, those who are relatively young and without COPD. These pts may be managed by a self -assessment system of FN, although the feasibility is still unknown. Methods: Self assessment system consists of three steps, such as, prescription of Ciprofloxacin 1200mg b.i.d., educating pts by the team (doctors, pharmacists, and nurses) with written material, and evaluation at the hospital if febrile episode (FE) continues for longer than 48 hours. FE is defined as body temperature higher than 38 °C. Frequency of FE, admission to the hospital, ICU stay, and 30 days mortality rate were assessed retrospectively. Results: From Aug. 2006 to Oct. 2011, 476 pts were treated in ambulatory chemotherapy center under self-assessment system. Median age was 58 years old (range; 17 - 82), 87 % of them were under 60 years old. Literacy rate was 100 %. All had solid tumors, 75 % of them had breast (n= 157) or GYN (ovary and primary peritoneal cancer; n = 155, cervix; n = 40, corpus; n = 4) malignancy. Platinum based regimens (n = 184) and anthracycline based regimens (n = 131) were dominant. FE occurred in 159 pts (33.4%). Forty three pts (9%) were admitted to the hospital. Two pts were admitted to ICU. 30 days mortality rate was 0 %. The median MASCC score of admitted pts was 21 (range; 14 - 21). About half (47 %) had high risk score (&lt; 20). Conclusions: In areas with limited resources, self assessment of FN can be an alternative option, although that should be applied to young and literate pts educated by skilled medical team.
Erratum: Cloning of the human Aflatoxin B1-aldehyde reductase gene at lp35-lp36,1 in region frequently altered in human tumor cells (Cancer Research (November 15, 1998) 58 (5014-5018))
Authors: C. Praml, L. Savelyeva, P. Perri, Manfred Schwab
Journal: Cancer Research (1999)